Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) was the recipient of a large growth in short interest in January. As of January 31st, there was short interest totalling 624,491 shares, a growth of 7.1% from the January 15th total of 582,825 shares. Based on an average daily trading volume, of 163,453 shares, the short-interest ratio is presently 3.8 days. Currently, 1.3% of the company’s shares are sold short.
Shares of Hemispherx BioPharma stock traded up $0.01 on Monday, reaching $0.24. 211,800 shares of the company’s stock were exchanged, compared to its average volume of 316,343. Hemispherx BioPharma has a 52 week low of $0.15 and a 52 week high of $0.59.
Hemispherx BioPharma (NYSEAMERICAN:HEB) last posted its quarterly earnings results on Thursday, November 15th. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter. The business had revenue of $0.04 million during the quarter.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.thestockobserver.com/2019/02/11/hemispherx-biopharma-inc-heb-short-interest-update.html.
About Hemispherx BioPharma
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Further Reading: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.